JP7737983B2 - 抗体又は巨大タンパク質の延長された放出の為の剤形物 - Google Patents

抗体又は巨大タンパク質の延長された放出の為の剤形物

Info

Publication number
JP7737983B2
JP7737983B2 JP2022525785A JP2022525785A JP7737983B2 JP 7737983 B2 JP7737983 B2 JP 7737983B2 JP 2022525785 A JP2022525785 A JP 2022525785A JP 2022525785 A JP2022525785 A JP 2022525785A JP 7737983 B2 JP7737983 B2 JP 7737983B2
Authority
JP
Japan
Prior art keywords
dosage form
poly
antibody
prepolymer
mabx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500686A (ja
JP2023500686A5 (https=
Inventor
ステーンダム,ロブ
ゴインブラ,マリア
カタリナ ヒベイロアラウホ,ジョアナ
ズイデマ,ヨハン
ヘンツラー,ターニャ
クロッグ,アレクサンドラ
Original Assignee
インノコア テクノロジーズ ビー.ブイ.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インノコア テクノロジーズ ビー.ブイ. filed Critical インノコア テクノロジーズ ビー.ブイ.
Publication of JP2023500686A publication Critical patent/JP2023500686A/ja
Publication of JP2023500686A5 publication Critical patent/JP2023500686A5/ja
Application granted granted Critical
Publication of JP7737983B2 publication Critical patent/JP7737983B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022525785A 2019-11-01 2020-10-30 抗体又は巨大タンパク質の延長された放出の為の剤形物 Active JP7737983B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19206786 2019-11-01
EP19206786.6 2019-11-01
PCT/NL2020/050674 WO2021086188A1 (en) 2019-11-01 2020-10-30 Dosage form for extended release of an antibody or large protein

Publications (3)

Publication Number Publication Date
JP2023500686A JP2023500686A (ja) 2023-01-10
JP2023500686A5 JP2023500686A5 (https=) 2024-12-19
JP7737983B2 true JP7737983B2 (ja) 2025-09-11

Family

ID=68426231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525785A Active JP7737983B2 (ja) 2019-11-01 2020-10-30 抗体又は巨大タンパク質の延長された放出の為の剤形物

Country Status (4)

Country Link
US (1) US20220409730A1 (https=)
EP (1) EP4051233A1 (https=)
JP (1) JP7737983B2 (https=)
WO (1) WO2021086188A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102024129442A1 (de) 2024-10-11 2026-04-16 Universität Potsdam, Körperschaft des öffentlichen Rechts Polymer-gekoppelte antikörper und antikörperfragmente

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503524A (ja) 1998-02-23 2002-02-05 マサチューセッツ インスティテュート オブ テクノロジー 生分解性形状記憶ポリマー
US20130209568A1 (en) 2010-07-09 2013-08-15 Innocore Technologies B.V. Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides
JP2014521762A (ja) 2011-07-22 2014-08-28 インノコア テクノロジーズ ビー.ブイ. 生物活性化合物の制御放出のための生物分解性、半結晶性、相分離、熱可塑性マルチブロックコポリマー

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503524A (ja) 1998-02-23 2002-02-05 マサチューセッツ インスティテュート オブ テクノロジー 生分解性形状記憶ポリマー
US20130209568A1 (en) 2010-07-09 2013-08-15 Innocore Technologies B.V. Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides
JP2014521762A (ja) 2011-07-22 2014-08-28 インノコア テクノロジーズ ビー.ブイ. 生物活性化合物の制御放出のための生物分解性、半結晶性、相分離、熱可塑性マルチブロックコポリマー

Also Published As

Publication number Publication date
JP2023500686A (ja) 2023-01-10
US20220409730A1 (en) 2022-12-29
EP4051233A1 (en) 2022-09-07
WO2021086188A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
US8728525B2 (en) Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
CN108366968B (zh) 制造蛋白质微粒的组合物和方法
CA2566075A1 (en) Microspheres comprising protein and showing injectability at high concentrations of said agent
US20230414716A1 (en) Sustained release formulations using non-aqueous emulsions
US12350374B2 (en) Fabrication of protein-encapsulating microgels
JP7737983B2 (ja) 抗体又は巨大タンパク質の延長された放出の為の剤形物
AU2025234155A1 (en) Sustained release formulations using non-aqueous membrane emulsification
US20250073179A1 (en) Formulations comprising a therapeutic protein and at least one stabilizer
IL303232A (en) Formulations
EA048265B1 (ru) Составы с замедленным высвобождением с применением неводного мембранного эмульгирования
HK40095488A (zh) 包含治疗性蛋白质和至少一种稳定剂的制剂
EA047559B1 (ru) Составы длительного высвобождения с использованием неводных эмульсий
HK1251461B (en) Compositions and methods of manufacturing protein microparticles

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240911

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241211

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20241211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250530

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250901

R150 Certificate of patent or registration of utility model

Ref document number: 7737983

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150